These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25252589)

  • 61. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
    Bhargava B; Reddy NK; Karthikeyan G; Raju R; Mishra S; Singh S; Waksman R; Virmani R; Somaraju B
    Catheter Cardiovasc Interv; 2006 May; 67(5):698-702. PubMed ID: 16575925
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Paclitaxel-incorporated nanoparticles of hydrophobized polysaccharide and their antitumor activity.
    Lee SJ; Hong GY; Jeong YI; Kang MS; Oh JS; Song CE; Lee HC
    Int J Pharm; 2012 Aug; 433(1-2):121-8. PubMed ID: 22561793
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial.
    Verheye S; Agostoni P; Dawkins KD; Dens J; Rutsch W; Carrie D; Schofer J; Lotan C; Dubois CL; Cohen SA; Fitzgerald PJ; Lansky AJ
    JACC Cardiovasc Interv; 2009 Mar; 2(3):205-14. PubMed ID: 19463427
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels.
    Hu Q; Gao X; Kang T; Feng X; Jiang D; Tu Y; Song Q; Yao L; Jiang X; Chen H; Chen J
    Biomaterials; 2013 Dec; 34(37):9496-508. PubMed ID: 24054848
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Paclitaxel-induced arterial wall toxicity and inflammation: tissue uptake in various dose densities in a minipig model.
    Radeleff B; Lopez-Benitez R; Stampfl U; Stampfl S; Sommer C; Thierjung H; Berger I; Kauffmann G; Richter GM
    J Vasc Interv Radiol; 2010 Aug; 21(8):1262-70. PubMed ID: 20656224
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A PTX/nitinol stent combination with temperature-responsive phase-change 1-hexadecanol for magnetocaloric drug delivery: Magnetocaloric drug release and esophagus tissue penetration.
    Jin Z; Wu K; Hou J; Yu K; Shen Y; Guo S
    Biomaterials; 2018 Jan; 153():49-58. PubMed ID: 29101815
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [French comment on article Efficacy of a paclitaxel-eluting biliary metal stent with sodium caprate in malignant biliary obstruction: a prospective randomized comparative study].
    Endoscopy; 2019 Sep; 51(9):904. PubMed ID: 31461776
    [No Abstract]   [Full Text] [Related]  

  • 70. Interest of a new biodegradable stent coated with paclitaxel on anastomotic wound healing after biliary reconstruction.
    Shi J; Lv Y; Yu L; Zhang B; Zhang X; Fan C; Geng Z
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1415-23. PubMed ID: 23669325
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antitumor effect of the paclitaxel-eluting membrane in a mouse model.
    Park JS; Jeong S; Lee DH; Maeng JH; Park IS; Park S
    Oncol Lett; 2018 Oct; 16(4):4537-4542. PubMed ID: 30214588
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Crystalline paclitaxel coated DES with bioactive protective layer development.
    Farah S; Domb AJ
    J Control Release; 2018 Feb; 271():107-117. PubMed ID: 29289571
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synthesis, characterization, and paclitaxel release from a biodegradable, elastomeric, poly(ester urethane)urea bearing phosphorylcholine groups for reduced thrombogenicity.
    Hong Y; Ye SH; Pelinescu AL; Wagner WR
    Biomacromolecules; 2012 Nov; 13(11):3686-94. PubMed ID: 23035885
    [TBL] [Abstract][Full Text] [Related]  

  • 74. IN-1233-eluting covered metallic stent to prevent hyperplasia: experimental study in a rabbit esophageal model.
    Kim EY; Song HY; Kim JH; Fan Y; Park S; Kim DK; Lee EW; Na HK
    Radiology; 2013 May; 267(2):396-404. PubMed ID: 23315658
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Polyurethane membrane with porous surface for controlled drug release in drug eluting stent.
    Seo EH; Na K
    Biomater Res; 2014; 18():15. PubMed ID: 26331066
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Paclitaxel-coated stents to prevent hyperplastic proliferation of ureteral tissue: from in vitro to in vivo.
    Kram W; Rebl H; Wyrwa R; Laube T; Zimpfer A; Maruschke M; Frank M; Vollmar B; Kundt G; Schnabelrauch M; Nebe B; Buchholz N; Hakenberg OW
    Urolithiasis; 2020 Feb; 48(1):47-56. PubMed ID: 30259058
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Covalent Polyisobutylene-Paclitaxel Conjugates for Controlled Release from Potential Vascular Stent Coatings.
    Trant JF; McEachran MJ; Sran I; Turowec BA; de Bruyn JR; Gillies ER
    ACS Appl Mater Interfaces; 2015 Jul; 7(26):14506-17. PubMed ID: 26066902
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In Vitro and Ex Vivo Permeability Studies of Paclitaxel and Doxorubicin From Drug-Eluting Biodegradable Ureteral Stents.
    Barros AA; Oliveira C; Reis RL; Lima E; Duarte ARC
    J Pharm Sci; 2017 Jun; 106(6):1466-1474. PubMed ID: 28257819
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fabrication and characterization of gefitinib-releasing polyurethane foam as a coating for drug-eluting stent in the treatment of bronchotracheal cancer.
    Chen W; di Carlo C; Devery D; McGrath DJ; McHugh PE; Kleinsteinberg K; Jockenhoevel S; Hennink WE; Kok RJ
    Int J Pharm; 2018 Sep; 548(2):803-811. PubMed ID: 29031981
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Functional Properties of Polyurethane Ureteral Stents with PLGA and Papaverine Hydrochloride Coating.
    Antonowicz M; Szewczenko J; Jaworska J; Jelonek K; Joszko K; Gzik-Zroska B; Nuckowski PM; Bryniarski P; Paszenda Z; Nakonieczny DS; Barabaszová KČ; Kasperczyk J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.